Kobayashi Pharmaceutical Co., Ltd. (TYO:4967)
Japan
· Delayed Price · Currency is JPY 5,631.00
-32.00 (-0.57%)
Mar 13, 2025, 3:30 PM JST
Kobayashi Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Net Income | 13,914 | 27,559 | 27,950 | 27,636 | 26,635 | Upgrade
|
Depreciation & Amortization | 8,022 | 6,057 | 5,358 | 4,835 | 4,106 | Upgrade
|
Loss (Gain) From Sale of Assets | 50 | 118 | 121 | 378 | 1,186 | Upgrade
|
Loss (Gain) From Sale of Investments | -635 | -436 | 89 | -84 | -261 | Upgrade
|
Other Operating Activities | -7,493 | -8,359 | -8,007 | -8,396 | -7,900 | Upgrade
|
Change in Accounts Receivable | 4,780 | -3,781 | 8,296 | -1,523 | 1,588 | Upgrade
|
Change in Inventory | -1,144 | -3,175 | -1,977 | -462 | 1,309 | Upgrade
|
Change in Accounts Payable | -9,447 | 361 | 515 | -158 | -4,178 | Upgrade
|
Change in Other Net Operating Assets | 3,199 | 16 | -431 | 193 | 1,501 | Upgrade
|
Operating Cash Flow | 11,246 | 18,360 | 31,914 | 22,419 | 23,986 | Upgrade
|
Operating Cash Flow Growth | -38.75% | -42.47% | 42.35% | -6.53% | 19.40% | Upgrade
|
Capital Expenditures | -26,056 | -12,756 | -14,747 | -3,663 | -3,795 | Upgrade
|
Sale of Property, Plant & Equipment | 22 | 5 | 3 | 10 | 15 | Upgrade
|
Cash Acquisitions | - | -11,176 | - | - | -11,355 | Upgrade
|
Divestitures | - | - | - | 200 | - | Upgrade
|
Sale (Purchase) of Intangibles | -573 | -813 | -1,482 | -522 | -354 | Upgrade
|
Investment in Securities | 8,053 | 5,395 | 2,168 | 12,095 | 2,838 | Upgrade
|
Other Investing Activities | 139 | -231 | -254 | -129 | -5 | Upgrade
|
Investing Cash Flow | -18,415 | -19,576 | -14,312 | 7,991 | -12,656 | Upgrade
|
Short-Term Debt Repaid | - | - | -1 | -12 | -5 | Upgrade
|
Total Debt Repaid | - | - | -1 | -12 | -5 | Upgrade
|
Net Debt Issued (Repaid) | - | - | -1 | -12 | -5 | Upgrade
|
Repurchase of Common Stock | - | -12,000 | -14,056 | -3,943 | - | Upgrade
|
Dividends Paid | -7,505 | -7,223 | -6,509 | -6,251 | -5,784 | Upgrade
|
Other Financing Activities | -263 | -240 | -193 | -171 | -230 | Upgrade
|
Financing Cash Flow | -7,768 | -19,463 | -20,759 | -10,377 | -6,019 | Upgrade
|
Foreign Exchange Rate Adjustments | 1,220 | 890 | 673 | 797 | -425 | Upgrade
|
Miscellaneous Cash Flow Adjustments | - | - | -22 | - | -2 | Upgrade
|
Net Cash Flow | -13,717 | -19,789 | -2,506 | 20,830 | 4,884 | Upgrade
|
Free Cash Flow | -14,810 | 5,604 | 17,167 | 18,756 | 20,191 | Upgrade
|
Free Cash Flow Growth | - | -67.36% | -8.47% | -7.11% | 28.52% | Upgrade
|
Free Cash Flow Margin | -8.94% | 3.23% | 10.33% | 12.08% | 13.41% | Upgrade
|
Free Cash Flow Per Share | -199.22 | 73.89 | 222.57 | 240.08 | 258.32 | Upgrade
|
Cash Interest Paid | 34 | 22 | 18 | 17 | 15 | Upgrade
|
Cash Income Tax Paid | 7,471 | 8,358 | 8,003 | 8,464 | 7,972 | Upgrade
|
Levered Free Cash Flow | -13,061 | 2,535 | 11,183 | 14,511 | 15,043 | Upgrade
|
Unlevered Free Cash Flow | -13,043 | 2,553 | 11,194 | 14,522 | 15,056 | Upgrade
|
Change in Net Working Capital | 9,880 | 5,952 | -5,499 | 2,347 | 1,032 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.